Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Autor:	Timothy Tree, Bernard V. North, Sophie Papa, K. Owczarczyk, Sultan Abdul-Jawad, Hartmut Kristeleit, Kamila Sychowska, Piers E.M. Patten, Sheeba Irshad, Clara Domingo-Vila, Catherine Tremain, Jennifer Vidler, Paul Fields, Thomas Lechmere, Emily Pollock, Rosalind Graham, Carl Graham, Jeffrey Seow, Leticia Monin, Thanussuyah Alaguthurai, Miguel Muñoz-Ruiz, Michael H. Malim, Jack Cooper, Katie J. Doores, Charalampos Gousis, Adrian Hayday, Duncan R. McKenzie, Angela Swampillai
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Cancer Research 2019-20 coronavirus outbreak Cellular immunity COVID-19 Vaccines Time Factors Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-Lymphocytes Antibodies Viral Article Immunogenicity Vaccine Neoplasms medicine Humans In patient BNT162 Vaccine Immunization Schedule Messenger RNA Immunity Cellular business.industry SARS-CoV-2 Vaccination Case-control study Cancer COVID-19 medicine.disease Virology Immunity Humoral Treatment Outcome Oncology Case-Control Studies Immunoglobulin G Host-Pathogen Interactions Spike Glycoprotein Coronavirus Cytokines business
Zdroj:	Cancer Cell
ISSN:	1878-3686 1535-6108
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f3f08b823ccf3eed45ea9d826b9afd http://europepmc.org/articles/PMC8506107 Zobrazit plný text záznamu